The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (hcc)
- Chiu, J
- Chan, P
- Wong, H
- Tang, YF
- Leung, R
- Poon, R
- Yao, TJ
- Chan, AC
- Pang, RW
- Fan, ST
- Yau, T
- Cheung, TT
DOIAbstract
Background. With the aging population, hepatocellular carcinoma (HCC) in the elderly represents a significant health burden. We aimed to evaluate and compare the efficacy and tolerability of single-agent sorafenib in treating elderly patients with advanced HCC versus the younger population. Methods. We retrospectively analyzed a consecutive cohort of advanced HCC patients with Child-Pugh A or B liver function and an Eastern Cooperative Oncology Group performance status score of 0-2 treated with sorafenib. The patients were categorized into older (age ≥70 years) and younger (age <70 years) groups. Treatment outcomes and related adverse events (AEs) were compared. Results. In total, 172 patients, 35 in the older (median age, 73 years) and 137...
Add to ORKG